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Abstract
Objectives: To identify genetic factors that would be predictive of individuals who require an implantable cardioverter-
defibrillator (ICD), we conducted a genome-wide association study among individuals with an ICD who experienced a life-
threatening arrhythmia (LTA; cases) vs. those who did not over at least a 3-year period (controls).
Background: Most individuals that receive implantable cardioverter-defibrillators never experience a life-threatening
arrhythmia. Genetic factors may help identify who is most at risk.
Methods: Patients with an ICD and extended follow-up were recruited from 34 clinical sites with the goal of oversampling
those who had experienced LTA, with a cumulative 607 cases and 297 controls included in the analysis. A total of 1,006
Caucasian patients were enrolled during a time period of 13 months. Arrhythmia status of 904 patients could be confirmed
and their genomic data were included in the analysis. In this cohort, there were 704 males, 200 females, and the average age
was 73.3 years. We genotyped DNA samples using the Illumina Human660 W Genotyping BeadChip and tested for
association between genotype at common variants and the phenotype of having an LTA.
Results and Conclusions: We did not find any associations reaching genome-wide significance, with the strongest
association at chromosome 13, rs11856574 at P=5610
26. Loci previously implicated in phenotypes such as QT interval
(measure of the time between the start of the Q wave and the end of the T wave as measured by electrocardiogram) were
not found to be significantly associated with having an LTA. Although powered to detect such associations, we did not find
common genetic variants of large effect associated with having a LTA in those of European descent. This indicates that
common gene variants cannot be used at this time to guide ICD risk-stratification.
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Introduction
Sudden cardiac arrest death (SCD) accounts for the loss of over
300,000 individuals each year in the United States [1] and
approximately 80% of those affected have underlying coronary
artery disease [1]. Many studies have provided evidence that there
is a genetic contribution to SCD by demonstrating family history
as being a risk factor for sudden cardiac death or cardiac arrest
[2,3,4]. In addition, multiple family studies have emphasized the
importance of heritability in SCD, with relative risks of 1.5 to 2.7
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who have died suddenly [5,6].
Recently, several studies have demonstrated specific gene
variants or genomic loci that are associated with SCD. These
include variants in the cardiac ion channels KCNQ1 and SCN5A
[7], nitric oxide synthase 1 adaptor protein [8], and a susceptibility
locus at 21q21 for ventricular fibrillation in patients who have had
acute myocardial infarction [9]. Furthermore, common variants in
at least 10 genomic loci have been correlated with QT duration, a
key indicator of cardiac repolarization [10,11].
While considerable research has been directed to the identifi-
cation of the genomics of life threatening arrhythmias (LTA), there
has not yet been a genome-wide assessment of patients who have
received an implantable cardioverter-defibrillator (ICD). ICDs are
implanted in approximately 250,000 individuals in the United
States annually for criteria that include diminished ejection
fraction, symptomatic heart failure, and to a lesser extent,
prolongation of the QRS interval or other primary arrhythmo-
genic cardiomyopathies. While ICDs have a success rate of more
than 97% for sensing and terminating the LTA [12], they are
never activated in approximately 80% of patients over the
duration of their lives [13–15]. Accordingly, our current criteria
for selecting patients for ICD therapy are rather crude,
particularly when one considers up-front cost approaching
$30,000 and the risk, albeit small, of infection, lead and device
malfunctions, and inappropriate shocks. At the same time, many
patients who could benefit from an ICD do not receive one.
Therefore, there is a need for better approaches to risk
stratification.
The hypothesis of the current study was that a genome-wide
assessment of patients with ICDs would identify common DNA
sequence variants associated with LTA and would refine ICD
selection criteria. Furthermore, by better defining the population
that could benefit from ICD therapy, the information might be
extrapolated to identify individuals at risk in the general
population who do not currently meet guidelines for primary
prevention ICD therapy.
We present the results of a retrospective analysis on patients
with an ICD and extended follow-up who had experienced LTA,
with a cumulative 607 cases and 297 controls included in the
analysis. We genotyped DNA samples using the Illumina
Human660 W Genotyping BeadChip and tested for association
between genotype at common variants and the phenotype of
having an LTA.
Methods
Ethics Statement
The Scripps Institutional Review Board reviewed and approved
the protocol entitled, MEDTRONIC GAME: Genetic Arrhyth-
mia Markers for Early Detection, IRB #08-4985, on June 6, 2008.
The protocol underwent continuing review on May 29, 2009 and
was closed with a Final Report on July 22, 2009. Written informed
consent was obtained from all participants involved in this study. A
copy of the last approved informed consent form is included as
Appendix S2.
Barbara G. Bigby, ALM, CIP, Scripps IRB Officer
Patient Population
The overall study design is shown in Figure 1. The inclusion
criteriaforallpatientswasthatanICDorcardiacresynchronization
therapy with defibrillator (CRT-D) was implanted, that the patient
was considered to be on optimal medical therapy by the treating
physician, that coronary artery disease was present with either prior
myocardial infarction, percutaneous coronary intervention or
coronary artery bypass surgery, and that the patient was of
European ancestry, with both parents and all 4 grandparents self-
reported as Caucasian. To qualify as cases, the additional inclusion
criteria were (1)age .40 years at the time of ICD implantation, and
(2) at least one fully documented life threatening arrhythmia, as
defined by a spontaneous ventricular arrhythmia with cycle length
#400 ms appropriately treated by the device. Two hundred of the
607 case patients were secondary prevention patients. Although all
patients in the study were expected to have a myocardial infarction
(MI) or coronary artery disease (CAD), it was not required that the
MI/CAD had to be diagnosed prior to the arrhythmic event date
for the secondary prevention patients. To qualify as controls,
patients required at least 3 years of ICD therapy with a center-
verified absence of any appropriately treated life-threatening
arrhythmias and no pre-implantation history of LTA or SCA (i.e.
a primary-prevention ICD indication). All control patients all had
ICDsfor primaryprevention. The control data were treatedas right
censoring at exam date. The demographic data from cases and
controls were compared using a t-test.
Patients were recruited at 34 sites across the United States
(Appendix S1) and the local institutional review boards approved
the protocol. A cohort of 500 cases and 500 controls was targeted
for enrollment in keeping with the success of the genome-wide
association studies that had a similar sample size in related
cardiovascular phenotypes of coronary heart disease [16], atrial
fibrillation [17], and QT interval [18]. All patients provided
informed consent prior to enrollment.
DNA isolation
All patients had a single tube of blood drawn at the time of
enrollment, which was collected centrally for subsequent DNA
extraction. A 0.2 ml aliquot of whole blood from each participant
was used for DNA isolation using the Qiagen QIAamp DNA Mini
Kit (Qiagen, Valencia, CA; Catalog #51185) and QiaCube
Robotic workstation for automated DNA purification. The typical
yield was 2–10 ug DNA from 0.2 ml blood. DNA concentrations
were determined using a nanodrop spectrophotometer and DNA
concentrations were adjusted to 50 ng/ul.
Genotyping and Data Quality Control
Genotyping was performed using the Illumina 660 W Bead-
Chip, following the manufacturer’s instructions. Genotypes were
Figure 1. Study design for genome-wide association study of
ICD activation with LTA.
doi:10.1371/journal.pone.0025387.g001
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rates. SNPs with call rates ,95%, or heterozygote frequencies
.65% after re-clustering were removed. Cluster separation scores
were generated using Illumina’s Genome Studio software. After
visual inspection of the range of cluster separation scores in this
dataset, thresholds for filtering were determined. Autosomal SNPs
with cluster separation scores #0.30 and X-chromosome SNPs
with cluster separation scores #0.38 were removed. Sample call
rates were recalculated and individuals with call rates ,99% were
removed (median call rate=99.989%). Genotype concordance
was calculated based on 12 duplicate samples (99.998%).
Additional quality control was undertaken using the genetic
analysis program PLINK [19]. Individuals were tested for
gender consistency, cryptic relatedness, and ancestry. All genders
determined by genotype data agreed with the clinical data.
Cryptic relatedness was tested using the –genome command,
which was run on SNPs that had been filtered for linkage
equilibrium (N=105,837, r
2,0.5 within a window of 50 SNPs).
Based on the proportion of relatedness (PI_HAT), 3 pairs of
samples were duplicate or twin samples (PI_HAT ,1) and 1 pair
of siblings (PI_HAT ,0.5) were present. In these cases, one
individual from each related pair was removed. Samples were
clustered by multidimensional scaling with HapMap III samples
using the set of 105,837 SNPs in linkage equilibrium. There were
4 samples that clustered outside the European (CEU and TSI)
ancestry groups and were removed. A total of 904 samples
passed all quality control filters, consisting of 607 cases, 297
controls.
SNPs were additionally filtered for minor allele frequency
(.0.01 in all samples) and Hardy-Weinberg equilibrium (P,10
26
in the controls). Finally, if SNPs were not present in dbSNP or did
not map uniquely to the reference genome, they were removed
(N=645). A total of 534,690 genotyped SNPs passed all quality
control filters.
Genotype Imputation
We imputed genotypes in genotyped individuals for all HapMap
(phase II, release 22) SNPs using the program MaCH [20] and an
r
2 threshold of 0.3. The best estimate of the quantitative allele
dosage was used as the predictor in association tests. The CEU
HapMap phased haplotypes were used as a reference (N=60
unrelated individuals). We estimated error rates by masking 1% of
the genotypes: genome-wide, the allelic error rate was 0.017 and
the genotypic error rate was 0.034.
Association
Case-control association was performed using logistic regression
in PLINK. For SNPs that were directly genotyped, the genotype
calls were used, while MaCH maximum likelihood dosages (0–2)
were used for SNPs that were imputed. Genetic background was
estimated using multidimensional scaling (MDS) and the top 10
MDS components were tested for association with the phenotype
[21]. Q-Q plots and genomic inflation factors were calculated in
PLINK using the –qq-plot command. The survival analysis was
performed using a Cox proportional hazards model as imple-
mented in the survival [22,23]. For the subset of cases with length
of follow-up (N=258), the time between implant and having an
adjudicated LTA was used, while for controls (N=297), the length
of follow-up was the time between implant date and exam date.
Gender was included as a covariate.
Power
Power was calculated for a range of allele frequencies and
genotyping relative risks based on sample size of cases and controls,
minor allele frequency, and genotyping relative risk assuming an
additive genetic model. Power at each genotypic relative risk was
calculated for an alpha of 5610
28 with CaTS [24].
CNV analysis
Copy number variants (CNVs) were predicted based on
intensity and genotype information from CNV and SNP probes
using PennCNV [25] (2010May01 version) and QuantiSNP [26]
(v2.3) with default parameters. A total of 33 samples were excluded
for high log R Ratio standard deviation, high waviness factor, or
drifting B allele frequency. CNVs covering at least 10 probes and
with a length of at least 100 kb were obtained using each method.
Regions that overlapped between the methods were merged and
analyses were performed using CNVs predicted by either method.
Only regions that overlapped between the methods were used in
the final analysis. There were 4,467 total autosomal CNV regions
consisting of 2,193 deletions and 2,274 duplications. Association
between cases and controls was run using the rare CNV
commands in PLINK with 100,000 permutations. Three analyses
were run: all CNVs, deletions (copy number=0 or 1), and
duplications (copy number=3, 4, or 5). P-values were calculated
using a max(T) permutation using the –mperm function in PLINK
[19]. This test compares each observed test statistic against the
maximum of all permuted statistics over all SNPs for each single
replicate. Regions with permuted P-value of less than 0.05 are
reported.
Results
The baseline demographics are summarized in Table 1, the
electrophysiologic features at baseline in Table 2, and medications
in Table 3.
Cases and controls differed by age, height, weight, location of
myocardial infarction, and age of first myocardial infarction
(Table 1). In addition, there were 704 males and 200 females in
the study. Gender specific differences were observed in mean left
ventricular ejection fraction (LVEF), weight, height, smoking, and
approximate age for the first MI.
The electrophysiologic characteristics at baseline also differed
between the groups with respect to incidence of atrioventricular
block, left bundle branch block, and a history of spontaneous
ventricular arrhythmia (Table 2). For the 102 patients with
qualifying tachycardias, the mean cycle length was 297 msec
(S.D.=56.5). The histogram of average ventricular cycle length
for these 102 patients is shown in Figure S1. Finally, there were
also some imbalances in baseline medications, particularly anti-
arrhythmic drugs (Table 3).
A genome-wide association was performed between individuals
that had an LTA (cases) and those that did not (controls) over the
course of at least three years (Figure 2). Gender and genetic
background were tested for association with case-control status,
were not found to be significant, and were not included in the
model. We did not detect any regions associated at P,5610
28
and report top regions at P,1610
25 (Table 4). The strongest
association at rs11856574 (P=5.0610
26), located in the hypo-
thetical gene KIAA0574 (hypothetical protein LOC23359). We
detected no evidence of population stratification (genomic inflation
factor=1.0035, Figure S2). On a subset of individuals for which
we had length of follow-up, we performed survival analysis GWA
(Figure S3). We did not detect any associations at P,5610
28, but
do note a region at 13q14.2 (rs2854357 P=8.2610
27) with a
consistent signal across multiple SNPs.
We looked specifically at P-values for 42 SNPs previously
reported to be implicated in prolonged QT duration or SCD
GWAS of ICD Activation
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Bonferroni corrected P-values (P,0.05/42=0.0012). Table S1
shows the P-values from directly genotyped or imputed genotypes
for these 42 SNPs, indicating that these SNPs may be of limited
prognostic value in identifying individuals likely to have an LTA
among those that are candidates for an ICD with prior myocardial
infarction.
We calculated our power to detect effects at an alpha of 10
27
for the sample sizes observed here. We were well powered to
detect effects of large effect size (OR.3.78) in common variants
(minor allele frequency (MAF).0.05) given our sample size (Figure
S4). For very common variants (MAF.0.25), we had 80% power
to detect effects of OR.2.15. Thus, it is unlikely that there is a
common variant with a large effect strongly associated with LTA
in individuals of European ancestry. Using genome-wide geno-
typing chips such as the Ilumina Human660 BeadChip, there is
good coverage of common variation in European ancestry
populations [31], however not all regions of the genome, in
particular regions of low linkage disequilibrium, may be covered
well.
We conducted a copy number variation analysis, using
QuantiSNP and PennCNV to estimate copy number variation
in each individual. CNV regions covering at least 10 probes and
100 kb from both methods were combined and tested for
association with case/control status in PLINK. There were no
regions that were associated at a multiple testing corrected P-value
less than 0.05 when all CNVs were combined. However, one
region on chromosome 16 (position 33,395,681–33,506,617) was
associated (minimum P=0.0097) when deletions alone were tested
(Figure S5). The region is flanked by a target of p53 (TP53TG3)
Table 2. Electrophysiological characteristics of cases and controls.
Electrophysiological Characteristics Case Arm (N=607) Control Arm (N=297) p-value
QRS.=120 ms 218 (54%) 122 (66%) 0.005**
Most Recent Intrinsic QRS Duration 128.4635.8 138.0639.8 0.004**
QRS Duration Not Available 203 (33%) 113 (38%) 0.182
Atrial Fibrillation 250 (41%) 145 (49%) 0.032*
Atrial Flutter 59 (10%) 30 (10%) 0.906
Atrial Tachycardia 24 (4%) 7 (2%) 0.248
AV Block 49 (8%) 53 (18%) ,0.0001**
AV Nodal Re-Entrant Tachycardia 4 (1%) 0 (0%) 0.309
AV Re-Entrant Tachycardia 1 (0%) 1 (0%) 0.549
Familial or Inherited Conditions with High Risk for VT 10 (2%) 1 (0%) 0.113
Intraventricular Conduction Delay 14 (2%) 13 (4%) 0.097
Left Bundle Branch Block 67 (11%) 50 (17%) 0.020*
Right Bundle Branch Block 38 (6%) 23 (8%) 0.400
doi:10.1371/journal.pone.0025387.t002
Table 1. Demographics of Cases and Controls at Time of ICD Implantation.
Patient Characteristics Case Arm (N=607) Control Arm (N=297) p-value
Age at Visit 71.1610.0 77.965.8 ,0.0001**
Gender (Male) 474 (89%) 230 (84%) 0.059
Most Recent LVEF 34.3612.9 36.7613.0 0.012*
LVEF Not Available 43 (7%) 22 (7%) 0.891
Weight (Kilograms) 90.1619.1 85.2615.9 ,0.0001**
Height (Meters) 1.7660.09 1.7460.09 0.010*
Body Mass Index 29.165.4 28.064.8 0.006**
RV - MI 44 (7%) 23 (8%) 0.788
LVA - MI 143 (24%) 89 (30%) 0.043*
LVP - MI 72 (12%) 19 (6%) 0.010*
Septal MI 37 (6%) 27 (9%) 0.128
Unknown MI Location 264 (43%) 118 (40%) 0.316
No Documented MI 100 (16%) 55 (19%) 0.453
Approximate Age at First MI 55.5611.6 60.9610.8 ,0.0001**
Family History of Sudden Cardiac Arrest or Death 148 (37%) 85 (43%) 0.154
Earliest Age of SCA/SCD for Parents/Siblings 61.7613.3 64.8613.5 0.115
doi:10.1371/journal.pone.0025387.t001
GWAS of ICD Activation
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of a region on chromosome X [32], we tested whether having a
CNV in this region was associated with gender and saw no
association. These CNVs require validation using quantitative
PCR and the association will require verification in a replication
study.
Discussion
Although ICDs are the main therapy for preventing SCD,
current criteria for patient selection remains suboptimal with only
approximately 20% requiring appropriate therapy over their
lifetime [13–15]. Through a genome-wide assessment, we were
Table 3. Baseline use of key medications.
Medication Use Case Arm (N=607) Control Arm (N=297) p-value
ACE Inhibitor Use - Current 294 (61%) 143 (58%) 0.426
ACE Inhibitor Use - Ever 444 (92%) 216 (87%) 0.046*
Angiotensin Receptor Blocker Use - Current 117 (36%) 57 (31%) 0.286
Angiotensin Receptor Blocker Use - Ever 174 (53%) 85 (46%) 0.119
Aldosterone Antagonist Use - Current 81 (27%) 31 (17%) 0.019*
Aldosterone Antagonist Use - Ever 130 (43%) 49 (27%) 0.001**
Beta Blocker Use - Current 467 (82%) 229 (82%) 1.000
Beta Blocker Use - Ever 559 (98%) 274 (98%) 0.800
Diuretics Use - Current 362 (74%) 188 (75%) 1.000
Diuretics Use - Ever 445 (92%) 223 (88%) 0.187
Anti-Arrhythmic/Class I Use - Current 44 (16%) 10 (6%) 0.002**
Anti-Arrhythmic/Class I Use - Ever 81 (29%) 19 (11%) ,0.0001**
Anti-Arrhythmic/Class II Use - Current 34 (13%) 16 (10%) 0.283
Anti-Arrhythmic/Class II Use - Ever 56 (22%) 16 (10%) 0.001**
Anti-Arrhythmic/Class III Use - Current 167 (42%) 36 (18%) ,0.0001**
Anti-Arrhythmic/Class III Use - Ever 259 (65%) 68 (34%) ,0.0001**
doi:10.1371/journal.pone.0025387.t003
Figure 2. Genome-wide association results of Cases with LTA vs. Controls without a LTA. Association 2log(P-values) are plotted
according to position in the genome. Points indicate genotyped (circle) or imputed (triangle) SNPs.
doi:10.1371/journal.pone.0025387.g002
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associated with appropriate ICD therapy for a LTA. We did detect
a marginally significant deletion associated with case status, but
this will require further validation and replication before it can be
considered a positive finding.
Our sample size was adequate to detect common sequence
variants that confer large effects with minor allele frequency of
0.25 or greater, many of which have previously been described to
be genome-wide associated with prolonged QT duration or in
candidate gene studies of SCD [6–11,17,18,27–30]. There are
several potential explanations for our findings. First, it is possible
that low frequency or rare sequence variants are associated with
appropriate ICD therapy. Indeed, several recent studies have
demonstrated that for common clinical phenotypes, multiple rare
variants with high penetrance may play an important role in
accounting for heritability [33–35]. It should be pointed out that
we screened common SNPs and copy number variants, but our
methodology did not address the detection of other sequence
variants such as small insertions, small deletions, or other forms of
structural genomic variation. Second, there may be relatively
common SNPs that confer a smaller effect (OR,2.0), but were not
detected in our cohort due to inadequate statistical power or due
to combining all types of LTA with rates #400 msec. This
potential shortcoming could be overcome by combining the data
from multiple like cohorts to determine whether gene variants with
minor allele frequency between 5% and 25% may, at least in part,
contribute to the heritability of LTA. Third, it remains possible
that propensity to develop an LTA is not genetically determined,
particularly in the types of patients who currently receive ICDs.
Such patients have markedly reduced systolic left ventricular
function. The likelihood of having appropriate ICD therapy
increases over time [36], and may be related to unfavorable
cardiac remodeling and adrenergic activation, representing more
of a mechanical/neural substrate than one that would implicate an
intrinsic abnormality of ion channels, repolarization, or electrical
dispersion. This possible explanation appears to be offset to some
degree by the remarkable finding of a common variant at 21q21
for ventricular fibrillation in patients with acute myocardial
infarction [9], although the arrhythmogenic milieu of acute
myocardial infarction differs from that of SCA in the stable
patient of systolic dysfunction. Fourth, it is possible that our cohort
was quite heterogeneous or suboptimal from a number of
standpoints. The lack of more extended follow-up may have led
to misclassification of phenotype, or the multiple paths to low
ejection fraction (e.g. myocardial infarction, diffuse coronary
artery disease cardiomyopathy) might represent a mosaic with
inadvertent lumping of phenotypes and diminished ability to
discern the genomic factors associated with any given subtype.
There is some indication from the subgroup of patient with
extended follow up in our study that this may represent a key issue
for detection of a significant genomic association.
It is worth noting that the study cohort is representative of the
demographics for patients in the United States who receive an
ICD. Patients who are in the control arm were slightly older, likely
because of the selection bias requiring that the individuals were
event-free and followed for a minimum of three years following the
device implant.
ICDs have been shown to reduce all-cause mortality by 26%
and 57% reduction of SCD in randomized controlled trials [36].
Observational data from 11 case-control cohorts involving 96,951
patients has been even more impressive with a 46% reduction of
all-cause mortality [36]. Yet the current selection criteria for ICD
implantation are far from optimal. About 80% of patients do not
require ICD activation for a life-threatening arrhythmia during
their lifetime after implantation. This lack of discriminative ability
is especially problematic given the cost of the devices and the array
of complications, albeit at low incidence, but including implan-
tation-related complications, lead failures, device malfunction, and
inappropriate shocks.
Moreover, a large proportion of patients with SCD do not meet
any current criteria for ICD therapy [1]. They have intact ejection
fraction and, at present, have no identifying risk markers. Had
genomic loci become evident from the present study of a cohort
with ICDs, it remains possible that the findings would be
informative or extrapolatable to the general population. With
the negative findings here, it remains unclear whether the ICD
cohort will prove to be representative of the at-large population
with risk of SCD.
There have been a very large number of genome-wide
association studies performed, and a subset of these have been
published for over 150 complex traits [37]. The negative GWAS
for LTA represents an important finding with the bias of
publication of only positive results. Here we have attempted to
identify genomic markers that would refine our appropriate
selection of patients who might receive an ICD, above and beyond
those patients with significant left-ventricular dysfunction. Our
inability to demonstrate a genomic marker should not be
considered an abject failure, but rather it can be viewed as the
first step that lays the groundwork for more intensive efforts such
as deep sequencing of candidate genes or much larger cohorts with
Table 4. Top regions associated at P,10
25.
Top SNP
Alleles
(A1/A2) Chr Pos
#SNPs at
P,10
24
Freq
(A1) OR (A1) P
Nearest gene, description, relative SNP
location
rs11856574* G/A 15 27518736 1/13 0.86 2.02 5.0610
26 KIAA0574, hypothetical protein, intron
rs482329* C/G 1 232883177 3/18 0.61 1.60 5.5610
26 IRF2BP2, interferon regulatory factor 2 binding
protein 2, 72 kb downstream
rs3848198* C/T 15 78426619 2/4 0.38 1.81 9.8610
26 ARNT2, Aryl hydrocarbon receptor nuclear
translocator 2; hypoxia associated transcription
factor, 57 kb upstream
rs6565373* T/C 16 86817543 0/1 0.59 0.32 9.8610
26 BANP, BTG3 associated nuclear protein isoform a;
negative regulator of p53 transcription, 149 kb
downstream
*imputed; #SNPs at P,10
24 indicates the number of SNPs at P,10
24 within +/2150 kb of the top SNP that were either directly genotyped or imputed (genotyped/
imputed).
doi:10.1371/journal.pone.0025387.t004
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of medicine, exemplifying device genomics, and especially at a
time of crisis in health care economics, deserves further study.
Supporting Information
Figure S1 Histogram of average ventricular cycle length
for subjects with qualifying tachycardia event (N=102).
(JPG)
Figure S2 Q-Q plot of LTA association. 2log(P-values) are
plotted according to expected (x-axis) and observed (y-axis) values.
Expected values were calculated in PLINK. Only directly
genotyped SNPs were used in this plot. A line is drawn at y=x.
(JPG)
Figure S3 Survival analysis Manhattan Plot. Genome-
wide association 2log(P-values) are shown for a survival analysis
using individuals (258 cases, 297 controls) for which we had length
of follow-up. Points indicate genotyped (circle) or imputed
(triangle) SNPs.
(JPG)
Figure S4 GWAS power. Genotypic relative risk (GRR)
detected at 80% power with at alpha=5610
28 for 607 cases
and 297 controls is plotted as a function of minor allele frequency.
(JPG)
Figure S5 Deletions overlapping chr 16 CNV associa-
tion. CNVs overlapping at least 10 probes and 100 kb were
predicted using PennCNV and QuantiSNP. CNVs predicted in
controls (blue) and cases (red) are plotted by location on the
chromosome. SNP and CNV markers are shown as asterisks or
triangles, respectively and plotted by location.
(JPG)
Table S1 Association at SNPs previously implicated in
sudden cardiac death, prolonged QT duration, atrial
fibrillation, or ventricular fibrillation.
(DOC)
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